Artivion (NYSE:AORT) Stock Price Down 6.6% – What’s Next?

Artivion, Inc. (NYSE:AORT)’s stock price was down 6.6% during trading on Wednesday . The company traded as low as $33.85 and last traded at $34.1850. Approximately 397,565 shares were traded during trading, a decline of 2% from the average daily volume of 403,735 shares. The stock had previously closed at $36.62.

Analyst Ratings Changes

A number of research firms recently weighed in on AORT. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Canaccord Genuity Group cut their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Stifel Nicolaus set a $55.00 price objective on Artivion in a report on Thursday, March 5th. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $50.47.

Artivion Stock Down 0.1%

The business has a fifty day moving average of $37.89 and a 200 day moving average of $41.89. The firm has a market cap of $1.63 billion, a P/E ratio of 170.71 and a beta of 1.63. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities research analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Insider Activity

In other Artivion news, EVP Lance A. Berry sold 6,316 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $238,618.48. Following the completion of the sale, the executive vice president owned 210,827 shares of the company’s stock, valued at approximately $7,965,044.06. This represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John E. Davis sold 4,573 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $172,767.94. Following the completion of the sale, the insider owned 230,794 shares in the company, valued at approximately $8,719,397.32. This trade represents a 1.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 133,043 shares of company stock worth $4,977,158 over the last quarter. 7.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AORT. Vanguard Group Inc. increased its holdings in shares of Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after acquiring an additional 141,030 shares in the last quarter. Morgan Stanley grew its position in shares of Artivion by 0.8% in the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after purchasing an additional 18,248 shares during the period. State Street Corp increased its stake in Artivion by 2.9% during the 4th quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after purchasing an additional 44,641 shares in the last quarter. Fred Alger Management LLC increased its stake in Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after purchasing an additional 55,322 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after buying an additional 748,119 shares during the period. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.